title: Monomeric C-reactive protein decreases acetylated LDL uptake in human endothelial cells.
abstract: BACKGROUND
  C-reactive protein (CRP) is a risk marker for cardiovascular disease and has been implicated in atherogenesis. In atherosclerotic plaques, it colocalizes with oxidized LDL (oxLDL) and promotes oxLDL uptake by macrophages, suggesting an important cross-talk between CRP and lipid processing. A growing body of evidence indicates the existence of distinct configurations of human CRP, native pentameric (nCRP) and structurally modified monomeric (mCRP), that elicit opposing bioactivities in vitro and in vivo. Here, we tested the impact of mCRP and nCRP on the uptake of acetylated LDL (acLDL), which is internalized by receptors similar to those of oxLDL in human endothelial cells.
  
  
  METHODS
  We cultured human umbilical vein endothelial cells (HUVECs) for 8 h with mCRP or nCRP (10-100 mg/L) and measured the uptake of acLDL (10-100 mg/L) over a 20-h period by FACS analysis. To assess the receptors involved, we used function-blocking antibodies against Fc gamma receptor CD16 (FcgammaRIII) and CD32 (FcgammaRII), and RT-PCR analysis of CD16, CD32, and the receptor for oxidized LDL (LOX-1). Uptake of acLDL and CRP isoforms was visualized by immunofluorescence.
  
  
  RESULTS
  Culture of HUVECs with mCRP, but not nCRP, decreased uptake of acLDL, which was not prevented by anti-CD16 or anti-CD32 antibodies. LOX-1, CD16, and CD32 were undetectable by RT-PCR. Immunofluorescence showed decreased cytoplasmic acLDL staining in human umbilical vein endothelial cells (HUVECs) treated with mCRP, but not with nCRP.
  
  
  CONCLUSIONS
  Monomeric CRP, but not nCRP, decreased acLDL uptake in human endothelial cells independent of CD16, CD32, or LOX-1. Our data support a protective role of mCRP in cardiovascular disease.
authors.affiliation: Department of Medicine I, University of Würzburg, Würzburg, Germany. pelleas@t-online.de
authors.forename: Susanne B
authors.initials: SB
authors.lastname: Schwedler
authors.forename: Thomas
authors.initials: T
authors.lastname: Hansen-Hagge
authors.forename: Matthias
authors.initials: M
authors.lastname: Reichert
authors.forename: Daniel
authors.initials: D
authors.lastname: Schmiedeke
authors.forename: Reinhard
authors.initials: R
authors.lastname: Schneider
authors.forename: Jan
authors.initials: J
authors.lastname: Galle
authors.forename: Lawrence A
authors.initials: LA
authors.lastname: Potempa
authors.forename: Christoph
authors.initials: C
authors.lastname: Wanner
authors.forename: János G
authors.initials: JG
authors.lastname: Filep
mesh_terms: D002097:C-Reactive Protein / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000378:metabolism / Q000517:prevention & control; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism*; D058851:GPI-Linked Proteins; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism*; D055503:Protein Multimerization; D017452:Receptors, IgG / Q000235:genetics / Q000276:immunology; D051127:Scavenger Receptors, Class E / Q000235:genetics
chemical_list: C428200:FCGR3B protein, human; D058851:GPI-Linked Proteins; D008077:Lipoproteins, LDL; C495137:OLR1 protein, human; D017452:Receptors, IgG; D051127:Scavenger Receptors, Class E; C032629:acetyl-LDL; D002097:C-Reactive Protein